Factors influencing in-hospital mortality for salvage percutaneous transjugular intrahepatic portosystemic shunting in cirrhotic patients with recalcitrant variceal bleeding after failed endoscopic intervention
DOI:
https://doi.org/10.7196/SAMJ.2024.v114i1.1839Keywords:
in-hospital mortality, recalcitrant variceal bleedingAbstract
Background. Endoscopic therapy is the first-line treatment of choice for control of acute variceal bleeding (AVB). In high-risk patients with persistent AVB despite pharmacological treatment and endoscopic intervention, percutaneous transjugular intrahepatic portosystemic shunting (TIPS) provides a minimally invasive salvage method to reduce portal pressure and control bleeding.
Objectives. To evaluate factors influencing in-hospital mortality after salvage TIPS (sTIPS) in patients with exsanguinating variceal bleeding despite medical treatment and endoscopic intervention.
Methods. Clinical and laboratory data were analysed in all patients treated with sTIPS following failed endoscopic therapy for AVB between August 1991 and November 2020. Factors associated with and predictors of death were determined using bivariate analysis and univariate logistic regression analysis.
Results. Thirty-four patients (29 men, 5 women), mean age 52 years (range 31 - 80), received sTIPS for uncontrolled (n=11) or refractory (n=23) AVB. The causes of portal hypertension were alcohol-related (n=24) and non-alcohol-related cirrhosis. Salvage TIPS controlled bleeding in 32 patients, with recurrence in 1. Ten patients died in hospital (mean 4.8 days, range 1 - 10) of liver failure (n=4), multiorgan failure (n=3), alcoholic cardiomyopathy (n=2) and uncontrolled gastric variceal bleeding (n=1). On bivariate analysis, factors associated with death were Child-Pugh (C-P) score ≥10 (p=0.006), sodium Model for End-stage Liver Disease (MELD-Na) score ≥22 (p<0.001), ≥8 units of blood transfused (p<0.001), Sengstaken-Blakemore balloon tube placement (p<0.001), endotracheal intubation (p<0.001), inotropic support (p<0.001) and endoscopically uncontrolled bleeding (p<0.001). Univariate logistic regression analysis showed that the most significant predictors of mortality were inotrope dependency (odds ratio (OR) 134; p<0.001), endotracheal intubation (OR 99; p<0.001), endoscopically uncontrolled bleeding (OR 28; p=0.001), grade 3 ascites (OR 20.9; p=0.012) and C-P grade C (OR 8.8; p=0.011).
Conclusion. Salvage TIPS controlled variceal bleeding in 94% of patients after failed endoscopic therapy with 29% in-hospital mortality. The most significant predictors of mortality were C-P grade C, grade 3 ascites, inotrope requirement, endotracheal intubation and endoscopically uncontrolled bleeding.
References
Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology 2017;65(1):310-335. https://doi.org/10.1002/hep.28906
Tripathi D, Stanley AJ, Hayes PC, et al.; Clinical Services and Standards Committee of the British Society of Gastroenterology. U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut 2015;64(11):1680-1704. https://doi.org/10.1136/gutjnl-2015-309262
De Franchis R; Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol 2015;63(3):743-752. https://doi.org/10.1016/j.jhep.2015.05.022
Deltenre P, Trépo E, Rudler M, et al. Early transjugular intrahepatic portosystemic shunt in cirrhotic patients with acute variceal bleeding: A systematic review and meta-analysis of controlled trials. Eur J Gastroenterol Hepatol 2015;27(9):e1-9. https://doi.org/10.1097/MEG.0000000000000403
Manning C, Elzubeir A, Alam S. The role of pre-emptive transjugular intrahepatic portosystemic shunt in acute variceal bleeding: A literature review. Ther Adv Chronic Dis 2021;12:2040622321995771. https://doi.org/10.1177/2040622321995771
Loffroy R, Estivalet L, Cherblanc V, et al. Transjugular intrahepatic portosystemic shunt for the management of acute variceal hemorrhage. World J Gastroenterol 2013;19(37):6131-6143. https://doi. org/10.3748/wjg.v19.i37.6131
Von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. Lancet 2007;370(9596):1453-1457. https://doi.org/10.1016/S0140-6736(07)61602-X
Krige JE, Kotze UK, Bornman PC, Shaw JM, Klipin M. Variceal recurrence, rebleeding, and survival after endoscopic injection sclerotherapy in 287 alcoholic cirrhotic patients with bleeding esophageal varices. Ann Surg 2006;244(5):764-770. https://doi.org/10.1097/01.sla.0000231704.45005.4e
Krige JEJ, Bornman PC. Endoscopic therapy in the management of esophageal varices: Injection sclerotherapy and variceal ligation. In: Blumgart L, ed. Surgery of the Liver, Biliary Tract and Pancreas. 4th ed. Philadelphia: Saunders, Elsevier, 2007:1579-1593.
Krige JEJ, Beningfield SJ. Endoscopic therapy in the management of esophageal varices. In: Fischer J, ed. Mastery of Surgery. 7th ed. Philadelphia: Lippincott Williams & Wilkins, 2019:1384-1398.
Tripathi D, Stanley AJ, Hayes PC, et al. Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension. Gut 2020;69(7):1173-1192. https://doi.org/10.1136/ gutjnl-2019-320221
Horhat A, Bureau C, Thabut D, Rudler M. Transjugular intrahepatic portosystemic shunt in patients with cirrhosis: Indications and posttransjugular intrahepatic portosystemic shunt complications in 2020. United European Gastroenterol J 2021;9(2):203-208. https://doi.org/10.1177/2050640620952637
BañaresR,CasadoM,Rodríguez-LáizJM,etal.Urgenttransjugularintrahepaticportosystemicshunt for control of acute variceal bleeding. Am J Gastroenterol 1998;93(1):75-79. https://doi.org/10.1111/ j.1572-0241.1998.075_c.x
Le Moine O, Devière J, Ghysels M, et al. Transjugular intrahepatic portosystemic stent shunt as a rescue treatment after sclerotherapy failure in variceal bleeding. Scand J Gastroenterol Suppl 1994;207:23-28. https://doi.org/ 10.3109/00365529409104190
Vangeli M, Patch D, Burroughs AK. Salvage TIPS for uncontrolled variceal bleeding. J Hepatol 2002;37(5):703-704. https://doi.org/ 10.1016/s0168-8278(02)00321-5
Helton WS, Belshaw A, Althaus S, Park S, Coldwell D, Johansen K. Critical appraisal of the angiographic portacaval shunt (TIPS). Am J Surg 1993;165(5):566-571. https://doi.org/10.1016/s0002- 9610(05)80436-2
Bouzbib C, Cluzel P, Sultanik P, et al. Prognosis of patients undergoing salvage TIPS is still poor in the preemptive TIPS era. Clin Res Hepatol Gastroenterol 2021;45(6):101593. https://doi.org/10.1016/j. clinre.2020.101593
Tzeng W-S, Wu R-H, Lin C-Y, et al. Prediction of mortality after emergent transjugular intrahepatic portosystemic shunt placement: Use of APACHE II, Child-Pugh and MELD scores in Asian patients with refractory variceal hemorrhage. Korean J Radiol 2009;10(5):481-489. https://doi.org/10.3348/ kjr.2009.10.5.481
Heinzow HS, Lenz P, Köhler M, et al. Clinical outcome and predictors of survival after TIPS insertion in patients with liver cirrhosis. World J Gastroenterol 2012;18(37):5211-5218. https://doi.org/10.3748/ wjg.v18.i37.5211
Rubin RA, Haskal ZJ, O’Brien CB, Cope C, Brass CA. Transjugular intrahepatic portosystemic shunting: Decreased survival for patients with high APACHE II scores. Am J Gastroenterol 1995;90(4):556-563. 21. Maimone S, Saffioti F, Filomia R, et al. Predictors of rebleeding and mortality among patients with refractory variceal bleeding undergoing salvage transjugular intrahepatic portosystemic shunt (TIPS).
Dig Dis Sci 2019;64(5):1335-1345. https://doi.org/10.1007/s10620-018-5412-x
WalterA,RudlerM,OlivasP,etal.;SalvageTIPSGroup.Combinationofmodelforend-stageliverdisease and lactate predicts death in patients treated with salvage transjugular intrahepatic portosystemic shunt
for refractory variceal bleeding. Hepatology 2021;74(4):2085-2101. https://doi.org10.1002/hep.31913 23. Azoulay D, Castaing D, Majno P, et al. Salvage transjugular intrahepatic portosystemic shunt for uncontrolled variceal bleeding in patients with decompensated cirrhosis. J Hepatol 2001;35(5):590-
https://doi.org/10.1016/s0168-8278(01)00185-4
Jalan R, John TG, Redhead DN, et al. A comparative study of emergency transjugular intrahepatic
portosystemic stent-shunt and esophageal transection in the management of uncontrolled variceal
hemorrhage. Am J Gastroenterol 1995;90(11):1932-1937.
Chalasani N, Clark WS, Martin LG, et al. Determinants of mortality in patients with advanced
cirrhosis after transjugular intrahepatic portosystemic shunting. Gastroenterology 2000;118(1):138-
https://doi.org/10.1016/s0016-5085(00)70422-7
Rajan DK, Haskal ZJ, Clark TW. Serum bilirubin and early mortality after transjugular intrahepatic
portosystemic shunts: Results of a multivariate analysis. J Vasc Interv Radiol 2002;13(2 Pt 1):155-161.
https://doi.org/10.1016/s1051-0443(07)61932-0
Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000;31(4):864- 871. https://doi.org/10.1053/he.2000.5852
Brensing KA, Raab P, Textor J, et al. Prospective evaluation of a clinical score for 60-day mortality after transjugular intrahepatic portosystemic stent-shunt: Bonn TIPSS early mortality analysis. Eur J Gastroenterol Hepatol 2002;14(7):723-731. https://doi.org/10.1097/00042737-200207000-00003
Patch D, Nikolopoulou V, McCormick A, et al. Factors related to early mortality after transjugular intrahepatic portosystemic shunt for failed endoscopic therapy in acute variceal bleeding. J Hepatol 1998;28(3):454-460. https://doi.org/10.1016/s0168-8278(98)80320-6
Rajesh S, George T, Philips CA, et al. Transjugular intrahepatic portosystemic shunt in cirrhosis: An exhaustive critical update. World J Gastroenterol 2020;26(37):5561-5596. https://doi.org/10.3748/wjg. v26.i37.5561
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licensing Information
The SAMJ is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
Publishing Rights
Authors grant the Publisher the exclusive right to publish, display, reproduce and/or distribute the Work in print and electronic format and in any medium known or hereafter developed, including for commercial use. The Author also agrees that the Publisher may retain in print or electronic format more than one copy of the Work for the purpose of preservation, security and back-up.
